Работы, цитирующие эту работу

Работ: 3

Работа: CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

1. CAR-T cell combination therapy: the next revolution in cancer treatment

   Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa +8

   Обзорная статьяCAR-T cell therapy researchCancer Cell International2022Цитирований: 2

   ABIABI:AkademIndex/openalex/2022.review-article.000004

2. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives

   Muqadas Shahzadi, Hamad Rafique, Ahmad Waheed +4

   Обзорная статьяCAR-T cell therapy researchTherapeutic Advances in Vaccines and Immunotherapy2024Цитирований: 1

   ABIABI:AkademIndex/openalex/2024.review-article.000014

3. Genetic engineering in oncology based on CRISPR-Cas9 technology

   D. Polatova, А. Yu. Madaminov, А. V. Savkin +1

   СтатьяCRISPR and Genetic EngineeringSiberian Journal of Oncology2024Цитирований: 0

   ABIABI:AkademIndex/openalex/2024.article.008036